Individual InvestorsEmployee Shareholders Institutional InvestorsPrivate Companies Accredited InvestorsSeed & Angel InvestorsAsset Managers & Hedge FundsFamily OfficesVenture Capital FirmsWealth Managers & RIAsWho We Serve Trading Data Liquidity Programs Retirement Individual InvestingForge MarketplaceFind new private company investment opportunities​Browse CompaniesInstitutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Data solutionsForge PriceA proprietary indicative price, calculated daily, for approximately 200 pre-IPO companiesForge DataAnalyze private markets via Forge’s intuitive web application​Index solutionsForge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Forge Thematic BasketsExplore focused views into key private market themesLiquidity ProgramsRetain and reward employees with company-sponsored liquidity solutions like tender offers and customized programsSelf-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRAWhat We Do All insights Reports and highlights News and trends Private market education Tips and tutorials Forge Investment OutlookPrivate Market UpdatesIPO calendarEmerging trendsPrivate company newsUpcoming IPOsAll guidesPrivate market basicsPrivate shares transactionsValuations, pricing and market trendsSelling in the private marketFAQsGlossaryCompany page and tradesProof of ownershipBid and ask submissionsForge fund offeringsInsights About UsLeadershipPeople & CultureCareers About
Log InSign Up
Who We Serve
What We Do
Insights
About
Secondary marketplace / Trade private companies / Buy and sell ADARx Pharmaceuticals stock
ADARx Pharmaceuticals

ADARx Pharmaceuticals stock

$--
Register to buy and sell private company shares
For more details on financing and valuation of private companies similar to ADARx Pharmaceuticals before its IPO, register or login today.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Log In

ADARx Pharmaceuticals stock price

Price history chart

7D
1M
3M
6M
1Y
All
Forge Price
$--
No longer available
Forge Price valuation
$--

ADARx Pharmaceuticals stock FAQs

To buy and sell ADARx Pharmaceuticals stock

Can you buy ADARx Pharmaceuticals stock?

You can no longer buy ADARx Pharmaceuticals stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.

How to buy ADARx Pharmaceuticals stock?

You can no longer buy ADARx Pharmaceuticals stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.

Can you sell ADARx Pharmaceuticals stock?

You can no longer sell stock of ADARx Pharmaceuticals on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.

How to sell ADARx Pharmaceuticals stock?

You can no longer sell stock of ADARx Pharmaceuticals on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.

To learn more about ADARx Pharmaceuticals stock

Is ADARx Pharmaceuticals a public company?

ADARx Pharmaceuticals is now a public company traded on NASDAQ with ticker ADRX.

What is ADARx Pharmaceuticals’ stock price?

The stock price of ADARx Pharmaceuticals is not currently available.

What is ADARx Pharmaceuticals’ stock ticker symbol?

The ticker symbol of ADARx Pharmaceuticals is ADRX.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platforms for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

ADARx Pharmaceuticals funding rounds and valuation

Total funding $352.5M

Funding history chart

Funding round and deals details

Funding Date Round Amount Raised Price Per Share Post-Money Valuation 3 Key Investors
08/09/2023 Series C $200M $9.75 $848.26M Ascenta Capital, Bain Capital Life Sciences, Blackrock Holdings, Commodore Capital, Cormorant Asset Management, Hbm Healthcare Investments, Invus Capital, Lilly Asia Ventures, Marshall Wace, Orbimed, Redmile Group, Sr One Capital Management, Tcg Crossover Management, T. Rowe Price Associates, Venrock Healthcare Capital Partners, Vivo Capital
Price Per Share
$9.75
Shares Outstanding
20,515,872
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ascenta Capital, Bain Capital Life Sciences, Blackrock Holdings, Commodore Capital, Cormorant Asset Management, Hbm Healthcare Investments, Invus Capital, Lilly Asia Ventures, Marshall Wace, Orbimed, Redmile Group, Sr One Capital Management, Tcg Crossover Management, T. Rowe Price Associates, Venrock Healthcare Capital Partners, Vivo Capital
01/20/2023 Series B-1 $46M $7.80 $484.32M Ascenta Capital, Lilly Asia Ventures, Orbimed, Sirona Capital, Sr One Capital Management
Price Per Share
$7.80
Shares Outstanding
5,900,272
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ascenta Capital, Lilly Asia Ventures, Orbimed, Sirona Capital, Sr One Capital Management
09/08/2021 Series B $75M $6.00 $361.97M Lilly Asia Ventures, Orbimed, Sirona Capital, Sr One Capital Management
Price Per Share
$6.00
Shares Outstanding
12,506,015
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Lilly Asia Ventures, Orbimed, Sirona Capital, Sr One Capital Management
05/14/2021 Series A $31.5M $1.18 $52.5M Undislosed Investors
Price Per Share
$1.18
Shares Outstanding
26,726,324
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undislosed Investors

Company details

ADARx Pharmaceuticals is a company that specializes in genetic medicine designed to treat human diseases and ailments using mRNA transcripts. ADARx researches and develops its therapies through oligonucleotides delivery technology. The firm focuses on three main disease treatments: genetic diseases, cardiometabolic diseases, and central nervous system (CNS) diseases.
Founded
2019
Headquarters
San Diego, CA, United States
Leadership
Christopher Prentiss
Chief Financial Officer
Robert MacLeod Ph.D
Chief Scientific Officer
Rui Zhu Ph.D
Founder
Vice President
Zhen Li Ph.D
President
Chief Executive Officer
Board
Chen-Ming Yu MD
Board Member
Erez Chimovits
Board Member
Judith Li
Board Member
Lorence Kim MD
Board Member
Ricky Sun Ph.D
Board Member
Simeon George MD
Board Member
Yuan Sun
Board Member

ADARx Pharmaceuticals news and media highlights

Independent news coverage

Fresh off massive fundraising, ADARx preps 3rd clinical program and mulls IPO

2023 has been a banner year for San Diego-based siRNA biotech ADARx Pharmaceuticals, with two assets jumping to the clinic and $200 million brought in through one of the largest private financing rounds of the year. Next year could be even bigger, as ADARx collects early data on clinical programs that have caught the eye of investors and Big Pharmas. “The street has started to pay attention to us," CEO Zhen Li, Ph.D., told Fierce Biotech in an interview.

ADARx Pharmaceuticals Raises $200M in Series C Financing

ADARx Pharmaceuticals, Inc., a San Diego, CA-based clinical stage biotechnology company developing next generation RNA therapeutics, closed a $200m Series C financing. The round was led jointly by Bain Capital Life Sciences and TCGX and also included new investors Blackrock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus, Marshall Wace, Redmile Group, T. Rowe Price Associates Inc., Venrock Healthcare Capital Partners, and Vivo Capital, as well as existing investors, Ascenta Capital, Lilly Asia Ventures, OrbiMed, and SR One Capital Management.

RNA biotech ADARx hauls in $200M, almost doubling 2 previous raises combined

Who says crossover rounds are dying? ADARx has raked in a $200 million series C, almost twice as much as the previous two joint series B rounds combined. The question now is, how quickly can the biotech's RNA pipeline be expanded? The new financing shared Wednesday will help ADARx advance two lead assets—ADX-324 and ADX-038—into the clinic, though more precise timing wasn’t disclosed. Since September 2021, the biotech had raised $121 from a series B and series B-1 round. The latter was announced in January, adding $46 million to ADARx’s bank.

ADARx Raises $75 Million to Advance Growing Pipeline

ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA targeting therapeutics, today announced the completion of a $75 million Series B financing to advance its drug development pipeline. The Series B was co-led by SR One Capital Management and OrbiMed Advisors. Sirona Capital joined this financing as well as existing investors OrbiMed Advisors and Lilly Asia Ventures.

Explore private companies in the Biotech & Pharma sector

Sector: Healthcare
Subsector: Biotech & Pharma
Trade Metrics Last Funding Round
Company Forge Price Last Matched Round Post-Money Valuation 3 Price Per Share Amount Raised
Altos LabsAltos Labs$17.00 +$2.00 (13.33%)$xx.xxSeries C$6.33B$25.02$1.5B
ArteraAIArteraAINot available$xx.xxSeries Seed-3$408.31M$7.95$82.82M
Chai DiscoveryChai DiscoveryNot available$xx.xxSeries C$3.8B$178.05$400M
Colossal BiosciencesColossal BiosciencesNot available$xx.xxSeries C$10.32B$24.89$380M
Isomorphic LabsIsomorphic LabsNot available$xx.xxNot available------
Life BiosciencesLife BiosciencesNot available$xx.xxNot available------
Mammoth BiosciencesMammoth BiosciencesNot available$xx.xxSeries D-3$1.35B$13.45$15M
Precision NeurosciencePrecision NeuroscienceNot available$xx.xxSeries D$1.03B$7.20$250M
Terray TherapeuticsTerray TherapeuticsNot available$xx.xxSeries C$722.36M$10.28$125M
Torque TherapeuticsTorque TherapeuticsNot available$xx.xxNot available------

Forge is your trusted partner to buy and sell ADARx Pharmaceuticals stock

Forge is the trusted platform for buying and selling private company stock. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

Updated on: Sep 29, 2026

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. Actively traded companies are companies with a high market activity with the highest post-money valuation in the same sector.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.